At Neurelis, we don’t back down from challenges––we’re inspired to innovate meaningful solutions. We see possibilities rather than limitations for people living with neurological conditions. That’s why we are dedicated to developing life-changing treatments that empower people to define their own journey.
We have reached a milestone in patient care with the first FDA-approved treatment from Neurelis.
Neurelis has a proprietary technology portfolio that includes Intravail®, ProTek®, and Hydrogel™ for drug delivery enhancement. These three non-invasive drug delivery and stabilization technologies are applicable to a wide range of molecules, including therapeutic proteins, peptides, and non-peptide large and small molecules. Our technologies offer exceptional potential value in enhancing drug development and clinical performance.
You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.
Do you want to link to this third-party site and leave Neurelis.com?
You are about to enter a site containing information on Medical Affairs and Research that is intended for US healthcare professionals only. Please confirm you are a healthcare professional and you wish to proceed to the HCP-only site.